GlassScriptPhysician profile
Assem Z Farhat
NPI 1720070907
$9,362.62
in general payments reported to CMS, 2019-2025
26 companies · $3,835 in 2025
The $3,835 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $416 · 2021: $914 · 2022: $899 · 2023: $1,001 · 2024: $1,230 · 2025: $3,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,609 · Travel and Lodging: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.97 |
| Travel and Lodging | $2,457.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,311.15 | 2021-2025 | Micra, Linq II, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $658.71 | 2019-2024 | Assurity, Aveir, Optis |
| Abiomed | $529.20 | 2019-2024 | Impella |
| Medtronic Vascular, INC. | $500.85 | 2019-2020 | |
| Shockwave Medical, INC | $329.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $325.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $306.46 | 2019-2025 | Wainua |
| Cvrx, INC. | $175.08 | 2022-2025 | Barostim Neo System |
| Amgen INC. | $174.66 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $165.82 | 2019-2022 | |
| Pfizer INC. | $153.18 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $143.88 | 2019-2024 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $128.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.45 | 2019-2021 | |
| Astellas Pharma US INC | $76.99 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $72.55 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $54.13 | 2023-2025 | Evkeeza |
| Amarin Pharma, INC. | $32.95 | 2020-2021 | |
| Boston Scientific Corporation | $29.77 | 2022 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Bardy Diagnostics, INC. | $16.17 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.72 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.42 | 2020 | |
| Scpharmaceuticals INC. | $14.14 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.40 | 2021 | |
| Surmodics, INC. | $12.98 | 2023 | Pounce Thrombectomy System, Pounce Thrombectomy, Pounce Venous Thrombectomy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assem Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.